GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
19 articles on this topic
-
How to Inject Semaglutide Safely
Semaglutide goes into the fatty layer beneath the skin of the abdomen, front of the thigh, or back of the upper arm. The device and pharmacy label—not a generic online diagram—determine the exact technique and measured amount.
-
Is Tirzepatide a Peptide? A Clear Answer
Yes. Tirzepatide is a 39-amino-acid synthetic peptide, and it is also a dual GIP/GLP-1 receptor agonist. Those labels describe its structure and its action, respectively.
-
Tirzepatide Units to Mg: The Safe Conversion
Tirzepatide units to mg is not a fixed conversion. On a U-100 syringe, 20 units is 0.2 mL; the milligram amount depends on the vial concentration.
-
How Does Semaglutide Work? Four Effects Explained
Semaglutide activates one receptor but produces coordinated signals in the pancreas, stomach and brain. Its engineered C18 side chain keeps those signals available for about a week.
-
Semaglutide Brand Names: Ozempic, Wegovy, Rybelsus
Ozempic, Wegovy, and Rybelsus all contain semaglutide, but their approved uses and formats differ. Compounded semaglutide is not a brand or generic.
-
How Does Tirzepatide Work? The Dual Mechanism
Tirzepatide activates two nutrient-sensitive hormone receptors, not one. The result is a linked set of effects on insulin, glucagon, stomach emptying and the signals that shape hunger and fullness.
-
Where to Inject Tirzepatide: Abdomen, Thigh, Arm
Current Zepbound and Mounjaro labels name three subcutaneous areas: the abdomen, thigh, and back of the upper arm. This overview does not replace the product-specific instructions from the prescriber and dispensing pharmacy.
-
Compounded Semaglutide: What It Is in 2026
Compounded semaglutide is a patient-specific prescription, not a generic Ozempic or Wegovy. The ingredient form, dosing label, and post-shortage rules all matter.
-
Tirzepatide Brand Names: Mounjaro and Zepbound
The two U.S. tirzepatide brand names are Mounjaro and Zepbound, both made by Eli Lilly. They contain the same active ingredient but carry different approved uses; compounded tirzepatide is not a brand.
-
Semaglutide Pill vs Injection: What Exists
There is a semaglutide pill. There is no tirzepatide pill, and there is unlikely to be one. Understanding why comes down to what happens to a 39-amino-acid peptide in your stomach.
-
Microdosing Tirzepatide: What It Means
No trial has ever tested it, and the term has no clinical definition. That does not make it unreasonable — but it does change what you can honestly expect from it.
-
Semaglutide Dosage: The 17-Week Ladder
The weight-management schedule climbs through five doses over sixteen weeks before reaching 2.4 mg. That deliberate pace is the single best-supported way to make the first months tolerable.
-
Tirzepatide Dosage and the Titration Ladder
Every tirzepatide dose ladder starts at 2.5 mg and climbs in 2.5 mg steps no sooner than every four weeks. Understanding why that interval exists tells you most of what you need to know about your own schedule.
-
Tirzepatide Side Effects, From Common to Rare
Gastrointestinal effects are the ones almost everyone asks about — and across the tirzepatide dose range they affect 39% to 49% of people, concentrated in the weeks when the dose is going up.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-
Tirzepatide vs Semaglutide: The Head-to-Head Data
In the SURMOUNT-5 trial, adults with obesity but without diabetes averaged 20.2% body-weight loss on tirzepatide and 13.7% on semaglutide over 72 weeks.
-
Tirzepatide Clinical Trials: What the Data Show
Two phase 3 programmes, a cardiovascular outcome trial that reported in December 2025, and more than 18,000 participants — here is what the published evidence actually shows, dose by dose.
-
Semaglutide Weight Loss Results: 14.9% in 68 Weeks
Adults with obesity in the 68-week STEP 1 trial lost an average of 14.9% of their body weight on weekly semaglutide, while the placebo group averaged 2.4%.